NO20032181L - Anvendelse av CCI-779 som et antineoplastisk middel - Google Patents

Anvendelse av CCI-779 som et antineoplastisk middel

Info

Publication number: NO20032181L
Authority: NO; Norway
Prior art keywords: cci; antineoplastic agent; antineoplastic; agent; neoplasms
Prior art date: 2000-11-15

Application number

NO20032181A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032181D0 (no

Inventor

Jr James Joseph Gibbons

Philip Frost

Carolyn Mary Discafani-Marro

Gary Dukart

Lisa Anne Speicher

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-15

Filing date

2003-05-14

Publication date

2003-05-14

2003-05-14 Application filed by Wyeth Corp filed Critical Wyeth Corp

2003-05-14 Publication of NO20032181D0 publication Critical patent/NO20032181D0/no

2003-05-14 Publication of NO20032181L publication Critical patent/NO20032181L/no

Links

CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 2
229960000235 temsirolimus Drugs 0.000 title abstract 2
229940034982 antineoplastic agent Drugs 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20032181A 2000-11-15 2003-05-14 Anvendelse av CCI-779 som et antineoplastisk middel NO20032181L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24907700P	2000-11-15	2000-11-15
PCT/US2001/047324 WO2002040000A2 (en)	2000-11-15	2001-11-13	Use of cci-779 as an antineoplastic agent

Publications (2)

Publication Number	Publication Date
NO20032181D0 NO20032181D0 (no)	2003-05-14
NO20032181L true NO20032181L (no)	2003-05-14

Family

ID=22941961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032181A NO20032181L (no)	2000-11-15	2003-05-14	Anvendelse av CCI-779 som et antineoplastisk middel

Country Status (27)

Country	Link
US (3)	US20020091137A1 (hu)
EP (1)	EP1335725B1 (hu)
JP (4)	JP4472251B2 (hu)
KR (1)	KR100827942B1 (hu)
CN (2)	CN102058588A (hu)
AR (1)	AR031341A1 (hu)
AT (1)	ATE393629T1 (hu)
AU (2)	AU2731302A (hu)
BR (1)	BR0115323A (hu)
CA (1)	CA2429020C (hu)
CY (1)	CY1108109T1 (hu)
DE (1)	DE60133831T2 (hu)
DK (1)	DK1335725T3 (hu)
EA (1)	EA007096B1 (hu)
ES (1)	ES2305134T3 (hu)
HU (1)	HUP0400521A3 (hu)
IL (2)	IL155871A0 (hu)
MX (1)	MXPA03004192A (hu)
NO (1)	NO20032181L (hu)
NZ (1)	NZ539668A (hu)
PL (1)	PL207061B1 (hu)
PT (1)	PT1335725E (hu)
SG (1)	SG148031A1 (hu)
SI (1)	SI1335725T1 (hu)
TW (1)	TWI286074B (hu)
WO (1)	WO2002040000A2 (hu)
ZA (1)	ZA200304603B (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP3143995B2 (en)	2001-02-19	2025-01-15	Novartis Pharma AG	Rapamycin derivative for the treatment of lung cancer
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
US20020198137A1 (en) *	2001-06-01	2002-12-26	Wyeth	Antineoplastic combinations
JP2004532883A (ja) *	2001-06-01	2004-10-28	ワイス	抗腫瘍コンビネーション
JP4547911B2 (ja) *	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	リン含有化合物およびその用途
EP1516597A4 (en) *	2002-06-27	2010-11-10	Microport Medical Shanghai Co	MEDICINES ELUTIONSSTENT
KR101131794B1 (ko) *	2002-07-30	2012-03-30	와이어쓰 엘엘씨	Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
SI1635830T1 (sl) *	2002-09-17	2009-02-28	Wyeth Corp	Granulirana farmacevtska oblika rapamicin-estra cci-779
BR0316111A (pt)	2002-11-21	2005-09-13	Wyeth Corp	Métodos para diagnosticar rcc e outros tumores sólidos
WO2004072265A2 (en) *	2003-02-11	2004-08-26	Wyeth	Methods for monitoring drug activities in vivo
US7643943B2 (en)	2003-02-11	2010-01-05	Wyeth Llc	Methods for monitoring drug activities in vivo
US20050287532A9 (en) *	2003-02-11	2005-12-29	Burczynski Michael E	Methods for monitoring drug activities in vivo
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
BRPI0409632A (pt) *	2003-04-22	2006-04-25	Wyeth Corp	combinações antineoplásticas
US20060194211A1 (en) *	2003-04-29	2006-08-31	Burczynski Michael E	Methods for prognosis and treatment of solid tumors
AU2004261163A1 (en) *	2003-07-25	2005-02-10	Wyeth	CCI-779 lyophilized formulations
AR046194A1 (es) *	2003-11-04	2005-11-30	Mayo Foundation	Metodo de tratamiento del linfoma de celulas del manto
ES2298861T3 (es) *	2004-01-08	2008-05-16	Wyeth	Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.
AR047988A1 (es) *	2004-03-11	2006-03-15	Wyeth Corp	Combinaciones antineoplásicas de cci-779 y rituximab
PL1848414T3 (pl)	2005-02-03	2011-10-31	Wyeth Llc	Sposób leczenia nowotworu opornego na gefitinib
RU2007127499A (ru) *	2005-02-15	2009-03-27	Вайет (Us)	Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме
AR057854A1 (es) *	2005-11-04	2007-12-19	Wyeth Corp	Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
EP2275103B1 (en) *	2005-11-21	2014-04-23	Novartis AG	mTOR inhibitors in the treatment of endocrine tumors
EP1962819A1 (en) *	2005-12-20	2008-09-03	Wyeth	Control of cci-779 dosage form stability through control of drug substance impurities
DE102006011507A1 (de) *	2006-03-14	2007-09-20	Lts Lohmann Therapie-Systeme Ag	Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en)	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched temsirolimus
US8660003B2 (en) *	2007-10-03	2014-02-25	Genesis Technical Systems Corp.	Dynamic, asymmetric rings
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013205002B2 (en) *	2008-03-21	2016-09-15	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
AU2009225434B2 (en)	2008-03-21	2014-05-22	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
ES2692769T3 (es)	2008-06-17	2018-12-05	Wyeth Llc	Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CA2730715C (en)	2008-08-04	2013-10-01	Wyeth Llc	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
SG174382A1 (en)	2009-04-06	2011-11-28	Wyeth Llc	Treatment regimen utilizing neratinib for breast cancer
WO2010132233A1 (en) *	2009-05-13	2010-11-18	The Trustees Of The University Of Pennsylvania	Combination antineoplastic therapy
AU2011260016B2 (en) *	2010-06-02	2013-08-22	Fresenius Kabi Oncology Ltd.	Stable pharmaceutical compositions of Rapamycin esters
US9745941B2 (en) *	2014-04-29	2017-08-29	Ford Global Technologies, Llc	Tunable starter resistor
JP6533866B2 (ja) *	2015-08-24	2019-06-19	山西亜宝保健品有限公司ＳｈａｎｘｉＹａｂａｏＨｅａｌｔｈＰｒｏｄｕｃｔｓＣｏ．，Ｌｔｄ．	抗腫瘍薬を製造するための、ジヒドロキシアセトンの用途
CN111110676A (zh) *	2020-03-07	2020-05-08	天津医科大学总医院	阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en)	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
BE877700A (fr) *	1978-11-03	1980-01-14	Ayerst Mckenna & Harrison	Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en)	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US5206018A (en)	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4401653A (en)	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en)	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en)	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5321009A (en)	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
DK0525960T3 (da)	1991-06-18	1996-04-15	American Home Prod	Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
IL102414A (en)	1991-07-25	1996-08-04	Univ Louisville Res Found	Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5516781A (en)	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en)	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
ZA935112B (en) *	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5561138A (en)	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en)	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
US6511986B2 (en)	2000-08-11	2003-01-28	Wyeth	Method of treating estrogen receptor positive carcinoma
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
TWI233359B (en) *	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
UA77200C2 (en) *	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569

2001
- 2001-11-05 TW TW090127415A patent/TWI286074B/zh not_active IP Right Cessation
- 2001-11-13 DK DK01996175T patent/DK1335725T3/da active
- 2001-11-13 EP EP01996175A patent/EP1335725B1/en not_active Expired - Lifetime
- 2001-11-13 AU AU2731302A patent/AU2731302A/xx active Pending
- 2001-11-13 ES ES01996175T patent/ES2305134T3/es not_active Expired - Lifetime
- 2001-11-13 SI SI200130829T patent/SI1335725T1/sl unknown
- 2001-11-13 AT AT01996175T patent/ATE393629T1/de not_active IP Right Cessation
- 2001-11-13 WO PCT/US2001/047324 patent/WO2002040000A2/en active IP Right Grant
- 2001-11-13 PT PT01996175T patent/PT1335725E/pt unknown
- 2001-11-13 PL PL362740A patent/PL207061B1/pl unknown
- 2001-11-13 EA EA200300566A patent/EA007096B1/ru not_active IP Right Cessation
- 2001-11-13 DE DE60133831T patent/DE60133831T2/de not_active Expired - Lifetime
- 2001-11-13 SG SG200505237-8A patent/SG148031A1/en unknown
- 2001-11-13 JP JP2002542375A patent/JP4472251B2/ja not_active Expired - Lifetime
- 2001-11-13 CN CN2010101653331A patent/CN102058588A/zh active Pending
- 2001-11-13 HU HU0400521A patent/HUP0400521A3/hu unknown
- 2001-11-13 US US10/010,584 patent/US20020091137A1/en not_active Abandoned
- 2001-11-13 KR KR1020037006542A patent/KR100827942B1/ko not_active Expired - Lifetime
- 2001-11-13 NZ NZ539668A patent/NZ539668A/en unknown
- 2001-11-13 CA CA002429020A patent/CA2429020C/en not_active Expired - Lifetime
- 2001-11-13 BR BR0115323-4A patent/BR0115323A/pt not_active Application Discontinuation
- 2001-11-13 MX MXPA03004192A patent/MXPA03004192A/es active IP Right Grant
- 2001-11-13 CN CNA018189261A patent/CN1678312A/zh active Pending
- 2001-11-13 IL IL15587101A patent/IL155871A0/xx unknown
- 2001-11-14 AR ARP010105310A patent/AR031341A1/es unknown
2003
- 2003-02-26 US US10/374,644 patent/US7189735B2/en not_active Expired - Lifetime
- 2003-05-12 IL IL155871A patent/IL155871A/en active IP Right Grant
- 2003-05-14 NO NO20032181A patent/NO20032181L/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304603A patent/ZA200304603B/en unknown
2007
- 2007-02-01 US US11/701,109 patent/US7781446B2/en not_active Expired - Fee Related
- 2007-03-27 AU AU2007201324A patent/AU2007201324B2/en not_active Expired
2008
- 2008-06-02 CY CY20081100573T patent/CY1108109T1/el unknown
2009
- 2009-09-18 JP JP2009216883A patent/JP2010018620A/ja active Pending
2014
- 2014-01-15 JP JP2014005231A patent/JP2014088430A/ja not_active Withdrawn
2015
- 2015-12-10 JP JP2015241449A patent/JP2016094444A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2004517065A (ja)	2004-06-10
AU2731302A (en)	2002-05-27
JP2016094444A (ja)	2016-05-26
MXPA03004192A (es)	2003-09-22
EA200300566A1 (ru)	2003-10-30
CA2429020A1 (en)	2002-05-23
KR100827942B1 (ko)	2008-05-13
US7189735B2 (en)	2007-03-13
WO2002040000A3 (en)	2002-09-06
PT1335725E (pt)	2008-06-19
ES2305134T3 (es)	2008-11-01
NZ539668A (en)	2007-06-29
HUP0400521A2 (hu)	2004-06-28
IL155871A (en)	2012-03-29
HK1058008A1 (en)	2004-04-30
NO20032181D0 (no)	2003-05-14
AU2007201324A1 (en)	2007-04-19
US20030153593A1 (en)	2003-08-14
SI1335725T1 (sl)	2008-08-31
IL155871A0 (en)	2003-12-23
DE60133831T2 (de)	2009-05-20
JP2010018620A (ja)	2010-01-28
CN102058588A (zh)	2011-05-18
US20020091137A1 (en)	2002-07-11
DE60133831D1 (de)	2008-06-12
PL362740A1 (en)	2004-11-02
AU2007201324B2 (en)	2010-11-18
CA2429020C (en)	2009-05-26
JP4472251B2 (ja)	2010-06-02
ATE393629T1 (de)	2008-05-15
TWI286074B (en)	2007-09-01
ZA200304603B (en)	2004-09-13
SG148031A1 (en)	2008-12-31
US20070142425A1 (en)	2007-06-21
HUP0400521A3 (en)	2007-05-29
EA007096B1 (ru)	2006-06-30
BR0115323A (pt)	2004-02-17
WO2002040000A2 (en)	2002-05-23
EP1335725B1 (en)	2008-04-30
DK1335725T3 (da)	2008-06-30
AR031341A1 (es)	2003-09-17
JP2014088430A (ja)	2014-05-15
US7781446B2 (en)	2010-08-24
EP1335725A2 (en)	2003-08-20
CN1678312A (zh)	2005-10-05
KR20040029309A (ko)	2004-04-06
CY1108109T1 (el)	2014-02-12
PL207061B1 (pl)	2010-10-29

Publication	Publication Date	Title
NO20032181L (no)	2003-05-14	Anvendelse av CCI-779 som et antineoplastisk middel
EA200501251A1 (ru)	2008-12-30	Антинеопластические комбинации
MXPA03007140A (es)	2004-05-24	Derivados de carbolina.
DE69925133D1 (de)	2005-06-09	Pyrrolobenzodiazepine
NO20031672D0 (no)	2003-04-11	Aza- og polyaza-naftalenylkarboksamider for anvendelse som HIV-integraseinhibitorer
MXPA02012076A (es)	2003-06-06	Compuestos quimicos.
AU2001266575A1 (en)	2002-01-08	Chemical compounds
ATE346067T1 (de)	2006-12-15	Carbolinderivate
MXPA03002911A (es)	2003-09-10	Compuestos quimicos.
NO20040702L (no)	2004-05-19	Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
IL155590A0 (en)	2003-11-23	Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
DE60115466D1 (de)	2006-01-05	Wirkstoffvorläufer von imidazopyridin-derivaten
BR0210101A (pt)	2004-06-08	Combinações antineoplásticas
AR034071A1 (es)	2004-01-21	Combinaciones antineoplasicas
DE60112960D1 (de)	2005-09-29	Kondensierte pyridoindolderivate
AR029092A1 (es)	2003-06-04	Composiciones para el tratamiento del cabello
BR0209883A (pt)	2004-06-08	Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco
ATE259813T1 (de)	2004-03-15	Triazolopyrimidinderivate
NO20031414L (no)	2003-05-26	Ny oksabispidinforbindelse som er nyttig i behandlingen av hjertearrytmier
DE60127131D1 (de)	2007-04-19	Tricyclische imidazopyridine
ATE330958T1 (de)	2006-07-15	Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
ATE337320T1 (de)	2006-09-15	Indolderivate als pde5-inhibitoren
ES2185605T3 (es)	2003-05-01	2,3-dihidro-1h-5,9-dioxaciclohepta (f) inden-7-onas 1,2-sustituidas y benzo (b) (1,4)dioxepin-3 onas 7-sustituidas.
ECSP003440A (es)	2001-11-27	Nuevos compuestos de pirimidinona y procedimiento

Legal Events

Date	Code	Title	Description
2011-05-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application